BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home » targets

Articles Tagged with ''targets''

Cancer

WRN targeting may aid in the treatment of mismatch repair-deficient CRC

Jan. 13, 2023
Recent findings have suggested that MMR-deficient CRC cells are highly sensitive to the loss of bifunctional 3ʹ-5ʹ exonuclease/ATP-dependent helicase WRN.
Read More
3D illustration and light micrograph of lung cancer.
Cancer

IRE1 ablation enhances survival in NSCLC mice

Jan. 12, 2023
Mortality rates related to non-small-cell lung cancer (NSCLC) remain still high, with about 75% of patients getting little clinical benefit from therapy. Adverse conditions in the tumor microenvironment, such as hypoxia or oxidative stress, disrupt the protein-folding capacity of the endoplasmic reticulum (ER) in infiltrating cells, provoking cellular stress that activates the unfolded protein response (UPR) pathway to restore proteostasis in this cellular organelle. During ER stress, serine/threonine-protein kinase/endoribonuclease IRE1 exerts its endoribonuclease activity on XBP1 mRNA generating a splice variant that encodes XBP1s that induces UPR target gene expression.
Read More
Amyloid plaques forming between neurons
Neurology/Psychiatric

PLD3 deletion reduces spheroid size and restores axonal conduction in AD

Dec. 29, 2022
Researchers from Yale University and affiliated organizations published data from a study that aimed to assess the mechanistic and pathophysiological importance of plaque-associated axonal spheroids (PAASs) in Alzheimer’s disease (AD).
Read More
Melanoma cells stained with an H & E stain and magnified to 320x.
Immuno-oncology

Understanding how to optimally combine MEK inhibitors with immunotherapy in mutant melanomas

Dec. 28, 2022
Previous evidence suggests that MEK/BRAF inhibitors targeting aberrant activation of the mitogen-activated protein kinase (MAPK) signaling pathway can sensitize tumors to immunotherapy through different mechanisms. This occurs in NRAS/BRAF mutant melanoma, where kinase inhibitor treatment sensitizes tumors to immunotherapy, at least partly, through an increase in the average surface presentation of peptide major histocompatibility molecules (pMHC) molecules. However, the optimal combination, order and timing of administration of both therapeutic strategies remain unclear.
Read More
Pancreatic cancer cells.
Cancer

Targeting SLC4A4 overcomes pancreatic cancer resistance

Dec. 21, 2022
Tumors have a lower interstitial pH compared to healthy tissues, with tumor acidity having emerged as a driver of tumor progression as it can lead to tumor immune evasion. Solute carrier family 4 member 4 (SLC4A4), which encodes a sodium bicarbonate cotransporter involved in pH regulation and homeostasis in normal tissue, was the focus of studies in pancreatic cancer resistance in in vivo preclinical models. Researchers tested the impact of Slc4a4 deletion in cancer cells on tumor growth, anticancer immunity and response to immunotherapy in murine models of pancreatic ductal adenocarcinoma (PDAC).
Read More
Human natural killer cell
Immuno-oncology

Blocking the KIR2DL5/PVR pathway boosts NK cell-based cancer immunotherapy

Dec. 7, 2022
NK cell-based cancer immunotherapy has emerged as an anticancer treatment approach and is currently being tested in clinical trials. KIR2DL5, a member of the human killer cell immunoglobulin-like receptor (KIR) family, has recently been identified as a binding partner for poliovirus receptor (PVR). However, the biology and therapeutic potential of the KIR2DL5/PVR pathway remain widely unexplored.
Read More
Cancer

Surviving colon cancer cells activate P2X4-dependent mTOR pathway

Dec. 2, 2022
Goethe University Frankfurt researchers and their collaborators conducted a study to examine...
Read More
3D illustration of kidney cross section
Nephrology

EndoA2 as a new therapeutic target in renal fibrosis

Nov. 30, 2022
Endophilin A2 (EndoA2) is a member of the endophilin A family, and is involved in the regulation of neurological and cardiovascular diseases, as well as tumor formation. Researchers from the Second Affiliated Hospital of Guangzhou Medical University assessed the role of EndoA2 in renal fibrosis.
Read More
Liver anatomy illustration
Gastrointestinal

CLDN1 is a therapeutic target in primary sclerosing cholangitis

Nov. 22, 2022
Primary sclerosing cholangitis (PSC) is a disease affecting the bile ducts that can lead to end-stage liver disease and cholangiocarcinoma. Patients with this disease lack therapeutic treatment other than liver transplantation.
Read More
Illustration of vascular system in the legs
Cardiovascular

BAZ1A-AS1 behind neointima formation after saphenous vein graft disease

Nov. 21, 2022
Noncoding RNAs, such as long noncoding RNAs (lncRNAs), are important regulators and markers of cardiovascular diseases. Saphenous veins are frequently used in coronary artery bypass surgery, but about 50% of the saphenous vein grafts fail in the first 10 years after surgery due to neointima formation.
Read More
Previous 1 2 … 48 49 50 51 52 53 54 55 56 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • Amyloid beta peptides on neurons

    Amlogenyx’s AM-805 reduces amyloid plaques in AD

    BioWorld Science
    The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • Atai Therapeutics patents new 5-HT2 receptor agonists

    BioWorld Science
    Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing